Abstract
An easy-to-perform fluorometric enzyme immunocapture assay (FEIA) was developed by Labsystems, Helsinki, Finland, to detect toxoplasma-specific immunoglobulin M (IgM) in dried blood spots. Assay materials were distributed to two sites that have programs in place designed to identify infants born with congenital toxoplasma infection: the Statens Serum Institut, Copenhagen, Denmark, and the New England Regional Newborn Screening Program, Boston, Mass. Each site tested over 700 dried blood samples from healthy newborns to define a cutoff at the 99.5 percentile (5 enzyme immunounits for Copenhagen and 4 enzyme immunounits for Boston). Each site then applied its own cutoff of interpret results for dried blood spots prepared from either adults with serology suggestive of acute infection (Copenhagen) or infants determined to be congenitally infected on the basis of serological criteria (Boston). In Copenhagen, 35 of 38 adult samples were either positive to a small degree or borderline positive for IgA. These samples thus may not represent acute infection. In Boston, of 26 congenitally infected infants, 22 were positive by FEIA. The four infant specimens not positive by FEIA were either negative or borderline positive by the standard Boston assay. These results demonstrate that the IgM FEIA is a potential alternative to other filter paper assay for toxoplasma-specific IgM currently in use for newborns.
Full Text
The Full Text of this article is available as a PDF (169.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aspöck H., Pollak A. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria. Scand J Infect Dis Suppl. 1992;84:32–37. [PubMed] [Google Scholar]
- Guerina N. G., Hsu H. W., Meissner H. C., Maguire J. H., Lynfield R., Stechenberg B., Abroms I., Pasternack M. S., Hoff R., Eaton R. B. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. 1994 Jun 30;330(26):1858–1863. doi: 10.1056/NEJM199406303302604. [DOI] [PubMed] [Google Scholar]
- Ishikawa E., Imagawa M., Hashida S., Yoshitake S., Hamaguchi Y., Ueno T. Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. J Immunoassay. 1983;4(3):209–327. doi: 10.1080/15321818308057011. [DOI] [PubMed] [Google Scholar]
- Lebech M., Petersen E. Neonatal screening for congenital toxoplasmosis in Denmark: presentation of the design of a prospective study. Scand J Infect Dis Suppl. 1992;84:75–79. [PubMed] [Google Scholar]
- March S. C., Parikh I., Cuatrecasas P. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Anal Biochem. 1974 Jul;60(1):149–152. doi: 10.1016/0003-2697(74)90139-0. [DOI] [PubMed] [Google Scholar]
- Naot Y., Desmonts G., Remington J. S. IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr. 1981 Jan;98(1):32–36. doi: 10.1016/s0022-3476(81)80528-8. [DOI] [PubMed] [Google Scholar]
- Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol. 1983 Dec;131(6):2895–2902. [PubMed] [Google Scholar]
- Thulliez P. Screening programme for congenital toxoplasmosis in France. Scand J Infect Dis Suppl. 1992;84:43–45. [PubMed] [Google Scholar]
- Tuuminen T., Palomäki P., Rakkolainen A., Welin M. G., Weber T., Käpyaho K. 3-p-hydroxyphenylpropionic acid--a sensitive fluorogenic substrate for automated fluorometric enzyme immunoassays. J Immunoassay. 1991;12(1):29–46. doi: 10.1080/01971529108055055. [DOI] [PubMed] [Google Scholar]
- Wolf A., Cowen D., Paige B. HUMAN TOXOPLASMOSIS: OCCURRENCE IN INFANTS AS AN ENCEPHALOMYELITIS VERIFICATION BY TRANSMISSION TO ANIMALS. Science. 1939 Mar 10;89(2306):226–227. doi: 10.1126/science.89.2306.226. [DOI] [PubMed] [Google Scholar]